Skip to main content

Articles

Page 211 of 213

  1. The randomised, double-blind, placebo-controlled Systolic Hypertension in Europe trial (Syst-Eur 1) proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk of cardiovascula...

    Authors: Lutgarde Thijs, Jan A Staessen, Sonia Beleva, Willem H Birkenhäger, Christopher J Bulpitt, Hilde Celis, Astrid E Fletcher, Rumjana Kermova, Gastone Leonetti, Tovio Laks, Stefan Mantov, Choudomir Nachev, Cinzia Sarti, Jaakko Tuomilehto and Robert H Fagard
    Citation: Trials 2001 2:298
  2. Inflammatory cytokines may negatively influence contractility and contribute to the remodelling process in the failing myocardium. Traditional cardiovascular drugs appear to have little influence on the overal...

    Authors: Jan Kristian Damås, Lars Gullestad and Pål Aukrust
    Citation: Trials 2001 2:271
  3. Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the f...

    Authors: Curt D Furberg and Bertram Pitt
    Citation: Trials 2001 2:205
  4. Antithrombotic treatment is of proven importance in patients with acute coronary syndromes. There is now accumulating evidence from several clinical trials in patients with unstable angina pectoris that the lo...

    Authors: Walter Ageno and Menno V Huisman
    Citation: Trials 2001 2:233
  5. Cardiac rehabilitation (CR) is a commonly used treatment for men and women with cardiovascular disease. To date, no single study has conclusively demonstrated a comprehensive benefit of CR. Numerous individual...

    Authors: Scott A Lear and Andrew Ignaszewski
    Citation: Trials 2001 2:221
  6. Raised levels of both triglycerides and fibrinogen, each of which are reduced by bezafibrate, may contribute to lower extremity arterial disease (LEAD). This condition is characterized by a particularly high i...

    Authors: Thomas W Meade
    Citation: Trials 2001 2:195
  7. Limited information has been published regarding how specific processes for event adjudication can affect event rates in trials. We reviewed nonfatal myocardial infarctions (MIs) reported by site investigators...

    Authors: Kenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, Neal S Kleiman, Lisa G Berdan, Brian S Crenshaw, Barbara E Tardiff, Christopher B Granger, Ingrid DeJong, Manju Bhapkar, Petr Widimsky, Ramón Corbalon, Kerry L Lee, Jaap W Deckers, Maarten L Simoons, Eric J Topol…
    Citation: Trials 2001 2:187
  8. Clinical events committees (CEC) are used routinely to adjudicate suspected end-points in cardiovascular trials, but little information has been published about the various processes used. We reviewed results ...

    Authors: Kenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, Neal S Kleiman, Lisa G Berdan, Brian S Crenshaw, Barbara E Tardiff, Christopher B Granger, Ingrid DeJong, Manju Bhapkar, Petr Widimsky, Ramón Corbalon, Kerry L Lee, Jaap W Deckers, Maarten L Simoons, Eric J Topol…
    Citation: Trials 2001 2:180
  9. The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is a prospective, randomized, multicenter clinical trial of carotid endarterectomy (CEA) versus carotid artery stenting (CAS) as preve...

    Authors: Robert W Hobson II, Virginia J Howard, Thomas G Brott, George Howard, Gary S Roubin and Robert DG Ferguson
    Citation: Trials 2001 2:160
  10. Long-term treatment with angiotensin-converting enzyme inhibitors reduces post-infarction morbidity and mortality in patients with left ventricular (LV) systolic dysfunction or symptomatic heart failure. Until...

    Authors: Vernon VS Bonarjee and Kenneth Dickstein
    Citation: Trials 2001 2:151
  11. Randomized trials and observational studies, such as case-control studies, are often seen as opposing approaches. However, in many instances results obtained by different designs may complement each other. For...

    Authors: Frits R Rosendaal
    Citation: Trials 2001 2:109
  12. Data quality assurance and quality control are critical to the effective conduct of a clinical trial. In the present commentary, we discuss our experience in a large, multicenter stroke trial. In addition to s...

    Authors: DeJuran Richardson and Shande Chen
    Citation: Trials 2001 2:115
  13. Women may be at increased risk for venous thromboembolism (VTE) as compared with men. We studied the effects of genetic and biochemical markers of thrombophilia in women, in conjunction with other established ...

    Authors: Joel G Ray, Loralie J Langman, Marian J Vermeulen, Jovan Evrovski, Erik L Yeo and David EC Cole
    Citation: Trials 2001 2:141

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.0
    5-year Journal Impact Factor: 2.1
    Source Normalized Impact per Paper (SNIP): 0.733
    SCImago Journal Rank (SJR): 0.812

    Speed 2023
    Submission to first editorial decision (median days): 28
    Submission to acceptance (median days): 129

    Usage 2023
    Downloads: 6,282,238
    Altmetric mentions: 5,569